Therapeutic target database 2026: facilitating targeted therapies and precision medicine

Yintao Zhang; Ying Zhou; Hangwei Xu; Wanghao Jiang; Bo Li; Dianyu Lai; Cong Wan; Shanshan Wang; Mingxiao Zhao; Ying Tan; Songlin Lu; Tingting Fan; Xin Liu; Feng Zhu; Yuzong Chen

doi:10.1093/nar/gkaf1154

Therapeutic target database 2026: facilitating targeted therapies and precision medicine

Yintao Zhang, Ying Zhou, Hangwei Xu, Wanghao Jiang, Bo Li, Dianyu Lai, Cong Wan, Shanshan Wang, Mingxiao Zhao, Ying Tan, Songlin Lu, Tingting Fan, Xin Liu, Feng Zhu^*, Yuzong Chen^*

^*Corresponding author for this work

AoPHA Faculty

Research output: Contribution to journal › Article › peer-review

Abstract

Development of targeted therapeutics begins with the discovery and validation of therapeutic targets, which builds the foundation for rational drug design. Extensive information on target–disease associations, target perturbation profiles, drug bioactivity landscapes, and clinical profiles is critical for identifying disease-relevant targets, elucidating their biological functions, and assessing the therapeutic potential. Therapeutic target database 2026 represents a major update that expands multiple layers of data essential for drug discovery. Key expansions include (i) 306 247 target–disease associations covering 2912 targets, (ii) 10 506 perturbation profiles triggered by genetic modification or chemical interference on 2368 targets, (iii) multidimensional activity landscapes of 17 806 drugs, encompassing cytotoxic, antimicrobial-, and molecular-level activities, and (iv) abundant clinical profiles for 2234 approved drugs. As a result, this update provides expanded and curated information on 3798 targets and 40 398 drugs. To enhance usability and scalability, the database framework has been rebuilt, which can be freely accessible without any login requirement at https://idrblab.org/ttd/.

Original language	English
Pages (from-to)	gkaf1154
Journal	Nucleic Acids Research
DOIs	https://doi.org/10.1093/nar/gkaf1154
Publication status	Published - 2025

Access to Document

10.1093/nar/gkaf1154

Cite this

@article{069f647c613440fba4ae02870446838c,

title = "Therapeutic target database 2026: facilitating targeted therapies and precision medicine",

abstract = "Development of targeted therapeutics begins with the discovery and validation of therapeutic targets, which builds the foundation for rational drug design. Extensive information on target–disease associations, target perturbation profiles, drug bioactivity landscapes, and clinical profiles is critical for identifying disease-relevant targets, elucidating their biological functions, and assessing the therapeutic potential. Therapeutic target database 2026 represents a major update that expands multiple layers of data essential for drug discovery. Key expansions include (i) 306 247 target–disease associations covering 2912 targets, (ii) 10 506 perturbation profiles triggered by genetic modification or chemical interference on 2368 targets, (iii) multidimensional activity landscapes of 17 806 drugs, encompassing cytotoxic, antimicrobial-, and molecular-level activities, and (iv) abundant clinical profiles for 2234 approved drugs. As a result, this update provides expanded and curated information on 3798 targets and 40 398 drugs. To enhance usability and scalability, the database framework has been rebuilt, which can be freely accessible without any login requirement at https://idrblab.org/ttd/.",

author = "Yintao Zhang and Ying Zhou and Hangwei Xu and Wanghao Jiang and Bo Li and Dianyu Lai and Cong Wan and Shanshan Wang and Mingxiao Zhao and Ying Tan and Songlin Lu and Tingting Fan and Xin Liu and Feng Zhu and Yuzong Chen",

year = "2025",

doi = "10.1093/nar/gkaf1154",

language = "English",

pages = "gkaf1154",

journal = "Nucleic Acids Research",

issn = "1362-4962",

}

TY - JOUR

T1 - Therapeutic target database 2026: facilitating targeted therapies and precision medicine

AU - Zhang, Yintao

AU - Zhou, Ying

AU - Xu, Hangwei

AU - Jiang, Wanghao

AU - Li, Bo

AU - Lai, Dianyu

AU - Wan, Cong

AU - Wang, Shanshan

AU - Zhao, Mingxiao

AU - Tan, Ying

AU - Lu, Songlin

AU - Fan, Tingting

AU - Liu, Xin

AU - Zhu, Feng

AU - Chen, Yuzong

PY - 2025

Y1 - 2025

N2 - Development of targeted therapeutics begins with the discovery and validation of therapeutic targets, which builds the foundation for rational drug design. Extensive information on target–disease associations, target perturbation profiles, drug bioactivity landscapes, and clinical profiles is critical for identifying disease-relevant targets, elucidating their biological functions, and assessing the therapeutic potential. Therapeutic target database 2026 represents a major update that expands multiple layers of data essential for drug discovery. Key expansions include (i) 306 247 target–disease associations covering 2912 targets, (ii) 10 506 perturbation profiles triggered by genetic modification or chemical interference on 2368 targets, (iii) multidimensional activity landscapes of 17 806 drugs, encompassing cytotoxic, antimicrobial-, and molecular-level activities, and (iv) abundant clinical profiles for 2234 approved drugs. As a result, this update provides expanded and curated information on 3798 targets and 40 398 drugs. To enhance usability and scalability, the database framework has been rebuilt, which can be freely accessible without any login requirement at https://idrblab.org/ttd/.

AB - Development of targeted therapeutics begins with the discovery and validation of therapeutic targets, which builds the foundation for rational drug design. Extensive information on target–disease associations, target perturbation profiles, drug bioactivity landscapes, and clinical profiles is critical for identifying disease-relevant targets, elucidating their biological functions, and assessing the therapeutic potential. Therapeutic target database 2026 represents a major update that expands multiple layers of data essential for drug discovery. Key expansions include (i) 306 247 target–disease associations covering 2912 targets, (ii) 10 506 perturbation profiles triggered by genetic modification or chemical interference on 2368 targets, (iii) multidimensional activity landscapes of 17 806 drugs, encompassing cytotoxic, antimicrobial-, and molecular-level activities, and (iv) abundant clinical profiles for 2234 approved drugs. As a result, this update provides expanded and curated information on 3798 targets and 40 398 drugs. To enhance usability and scalability, the database framework has been rebuilt, which can be freely accessible without any login requirement at https://idrblab.org/ttd/.

U2 - 10.1093/nar/gkaf1154

DO - 10.1093/nar/gkaf1154

M3 - Article

SN - 1362-4962

SP - gkaf1154

JO - Nucleic Acids Research

JF - Nucleic Acids Research

ER -